PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Recruiting now

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.

Key facts

Study ID

NCT07184970

Run by

NYU Langone Health

People needed

60

Starts

2025-10-08

Expected to finish

2028-10-01

Last updated by the study team

2025-10-10

Who can join

Age: 40 and older, up to 95. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patients 40-95 years of age with biopsy-confirmed localized prostate cancer.
• Grade Group ≥2 (Gleason score 3+4 or higher).
• Unifocal disease visible on mpMRI.
• Patients undergoing HIFU as part of their standard of care
• PSA <20 ng/mL.
• No metastatic disease on PSMA PET/CT
• Willingness to comply with follow-up protocols (PSA testing, imaging, biopsies).

You may not qualify if…

• Evidence of metastatic disease on PSMA PET/CT.
• Allergy to POSLUMA or gadolinium.
• Inability to tolerate MRI due to claustrophobia or posture/back-hip issues.

Where it is running

• NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.